Melanotan II: Effects, Risks & What the Evidence Shows
Melanotan II is discussed online as a tanning peptide, but it acts on several melanocortin pathways at once. Here is what the small human studies observed, what the case literature records, and why a changing mole is never a cosmetic detail.
Reviewed September 11, 2026 · Educational resource · Not medical advice
Awaiting editorial release. This page is readable but withheld from search engines until scientific, medical, legal and regulatory review are complete.
- FDA approval
- Not FDA-approved for tanning or any human use
- Evidence base
- Two very small early human studies; case reports and reviews
- Regulatory watch
- Nomination withdrawn; further FDA advisory consultation planned
Important: This page describes research interest and regulatory status. It does not recommend use, establish safety or effectiveness, or offer access to Melanotan II. New or changing pigmented lesions, and any erection lasting four hours, require prompt medical assessment.
Overview
A pigment-stimulating peptide with effects beyond the skin.
Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH). It activates multiple melanocortin receptors rather than targeting only one pathway.
Its action at MC1R can increase eumelanin production in pigment-forming cells called melanocytes. Activity at other melanocortin receptors helps explain why early studies and online users also describe nausea, appetite changes, yawning, erections, and changes in sexual desire.
Melanotan II is not Melanotan I: Melanotan II is a cyclic, broadly acting research peptide. Afamelanotide—sometimes called Melanotan I—is a different drug delivered as a controlled-release implant and FDA-approved only for erythropoietic protoporphyria. Approval of afamelanotide does not make Melanotan II approved or interchangeable.
Claims & proposed mechanisms
One peptide, several receptor pathways.
Pigment signaling
MC1R activation increases signaling involved in melanin production. That can affect overall skin tone, freckles, and moles—not only the areas someone hopes to tan.
Central nervous system effects
MC3R and MC4R activity is associated with appetite, autonomic responses, sexual desire, and erections. These are pharmacologic effects, not proof of a safe consumer benefit.
Uncertain real-world exposure
Online products may differ in identity, purity, concentration, sterility, and storage. This makes a copied social-media “protocol” especially unreliable.
Reported experiences
What users commonly describe.
In online discussions, users commonly describe Melanotan II as a tanning peptide. Reported experiences include darker skin across the body, darkening freckles or moles, reduced appetite, and increased libido. Some users also discuss repeated use over short periods.
- “Darker all over”
- Users described generalized tanning and more noticeable freckles or moles.
- Less interest in food
- Appetite suppression appeared as a recurring user-reported effect.
- Higher libido
- Some users described increased desire; early small studies also observed erections in male participants.
- Repeated short courses
- Videos mentioned daily use and “loading” periods, but these are not validated medical instructions.
How to read these reports: Anecdotes can reveal questions worth investigating, but they cannot establish safety, dosage, product quality, or cause and effect. A 2021 analysis of 623 public forum entries found widespread misinformation, variable dosing, sunbed use, side effects, and risky practices around an unregulated product.
Evidence review
Human research is small; safety signals matter.
- Pilot phase I study · 3 men
Dorr et al., Life Sciences, 1996
Repeated subcutaneous exposure produced measurable pigmentation in two participants. Mild nausea was common; fatigue or somnolence occurred at a higher exposure, and yawning, stretching, and spontaneous erections were observed.
- Crossover study · 10 men
Wessells et al., Journal of Urology, 1998
Eight of ten participants developed clinically apparent erections after Melanotan II. Nausea, yawning/stretching, and decreased appetite occurred more often than with placebo. This small study does not establish general consumer safety.
- Safety review
Habbema et al., International Journal of Dermatology, 2017
The review found uncertainty about preparation, administration, and dosing, along with case reports of new or changing nevi and melanomas during or shortly after use. The authors noted that causation was not proven.
- Qualitative forum study
Gilhooley et al., Dermatology, 2021
Analysis of online discussions identified misinformation, variable administration practices, sunbed exposure, side effects, contamination concerns, polypharmacy, and infectious-disease risk.
Safety
Darkening a mole is not a cosmetic detail.
The research does not prove that Melanotan II causes melanoma. It also does not establish that Melanotan II is safe.
- New or changing lesions
- New moles, rapid change, asymmetry, irregular borders, multiple colors, bleeding, itching, or a lesion that looks different from the others should be assessed by a clinician or dermatologist.
- Prolonged erection
- An erection lasting four hours is a medical emergency because delayed treatment can cause permanent injury.
- Systemic reactions
- Published case reports describe severe toxicity including rhabdomyolysis, kidney dysfunction, and renal infarction. A case report cannot quantify risk, but it is a meaningful warning signal.
- Product quality
- Products sold as “research use only” may not have reliable identity, purity, sterility, dose accuracy, or cold-chain handling.
No tan is sun protection: No Melanotan II tan should be treated as sunscreen or protection from skin cancer. UV exposure and tanning beds still damage skin and increase skin-cancer risk.
Clinical context
Pigment change deserves assessment, not reassurance from a forum.
People often encounter Melanotan II while looking for an easier tan, appetite control, or a change in sexual response. Each of those goals has established, evaluated options worth discussing with a clinician, and each of the reported effects here comes from activity at receptors that also influence blood pressure, appetite, and pigment cells.
Take skin changes seriously
A mole that is new, growing, changing color, bleeding, or simply different from the others should be examined promptly rather than attributed to tanning.
Separate the evidence levels
Two very small early studies, a safety review, and a forum analysis are not the same as controlled evidence of benefit or a characterized safety profile.
Treat emergencies as emergencies
A prolonged erection, severe muscle pain with dark urine, or signs of kidney injury need urgent medical care, not a change in schedule.
Reader context: Find GLP-1 Care Now does not provide Melanotan II access: no prescribing, product sourcing, dosing, reconstitution, injection or nasal-administration guidance, or purchasing advice is offered through this research library. This page exists for education, risk recognition, and correcting misinformation.
Regulatory watch
Not FDA-approved for tanning—or any human use.
FDA materials identify Melanotan II as an unapproved new drug. FDA has also identified potential immunogenicity concerns for compounded products because peptide aggregation or related impurities may be present.
As of FDA’s April 22, 2026 update, the substance’s nomination was withdrawn and FDA planned further advisory-committee consultation. That change did not constitute approval or a finding of safety.
Common questions
Melanotan II FAQ
Frequently asked questions
What is Melanotan II?
Melanotan II is a synthetic cyclic peptide that activates several melanocortin receptors. Early studies observed increased pigmentation as well as effects involving nausea, appetite, yawning, sexual desire, and erections. It is not FDA-approved for human use.
Is Melanotan II FDA-approved?
No. Melanotan II is not FDA-approved for tanning or any other human use. It is different from prescription afamelanotide, a controlled-release implant approved only for a specific rare disorder.
Does Melanotan II cause melanoma?
A causal link has not been established, but published reports describe new, darkening, or changing moles and melanomas occurring during or after use. Because Melanotan II stimulates pigment-producing cells and long-term safety is unknown, new or changing lesions require prompt medical evaluation.
Why do people report darker freckles and moles?
Melanotan II activates the MC1 receptor involved in melanin production, so pigmentation may appear in freckles and moles as well as other skin. A changing mole should never be assumed to be a harmless tanning effect.
Can Melanotan II increase libido?
Small early human studies observed increased sexual desire and erections in some male participants. These studies do not establish Melanotan II as an approved or safe sexual-health treatment.
Does Melanotan II suppress appetite?
Decreased appetite has been reported in early studies and by online users, but Melanotan II is not an approved weight-loss treatment and has not been established as safe for that purpose.
How fast does Melanotan II work?
Small historical studies observed pigmentation changes after repeated exposure, while online timelines vary widely. There is no FDA-approved product label or validated consumer protocol, so Find GLP-1 Care Now does not provide a use timeline.
How is Melanotan II taken?
Online sellers discuss injections and nasal sprays, but these are unapproved products of uncertain quality. Find GLP-1 Care Now does not provide administration or reconstitution instructions for Melanotan II.
What side effects have been reported?
Reports include nausea, flushing, fatigue or somnolence, yawning and stretching, reduced appetite, spontaneous or prolonged erections, blood-pressure changes, and new or changing pigmented lesions. Serious case reports include rhabdomyolysis, kidney injury, and renal infarction.
Does a Melanotan II tan protect against UV damage?
No Melanotan II tan should be treated as sunscreen or protection from skin cancer. UV exposure and tanning beds still damage skin and increase skin-cancer risk.
Related research
- GHK-CuA route-aware review of skin and tissue research, and the difference between cosmetic discussion and drug approval.
- LL-37Host-defence biology, the limits of laboratory evidence, and current U.S. regulatory status.
- What are peptides?Understand approved medicines, compounded products, research chemicals, and evidence quality.
This page is an educational research summary. It is not medical advice, not a recommendation to use any compound, and not an offer of access to one. Talk to a licensed clinician about your own care.
Find GLP-1 Care Now is owned by Athena Certification Center LLC. JourneyMeds is the founding sponsor. Sponsorship does not change organic provider rankings or editorial conclusions. Read the full ownership and advertising disclosure.
Last reviewed September 11, 2026. Regulatory status is checked on the review date and can change afterwards; follow the primary sources above for the current position.